enGene Therapeutics reported a $32.501 million net loss and $0.47 net loss per share for the three months ended July 31, 2026. The company has not generated Revenue since inception, leaving Research and Development spending, operating losses and available Shareholder Equity as key investor-facing financial measures.

Key Highlights

  • Shareholders’ equity stood at $288.322 million as of July 31, 2026.
  • Research and development expense declined to $20.090 million from $22.575 million in the comparable period.
  • General and administrative expense rose to $13.924 million from $7.372 million.

EnGene Therapeutics Inc. (NASDAQ: ENGN) reported a net loss of $32.501 million and a net loss per share of $0.47 for the three months ended July 31, 2026. The company has not generated revenue since inception and does not expect product-sale revenue in the near future, if at all. Operating expenses for the quarter totaled $34.014 million.

July Quarter Loss And EPS

The net loss per share was based on weighted-average common shares outstanding of 69,734,610 for the quarter. The company’s net loss for the nine months ended July 31, 2026 was $92.480 million, while its nine-month net loss per share was $1.34. Total operating expenses reached $97.167 million for that nine-month period. The company reported no product candidates approved for sale. Product-sale revenue would depend on successful clinical development and regulatory approval, while collaboration or licensing arrangements could also generate future revenue.

Expense Mix Shifts

Research and development expense was $20.090 million for the quarter, compared with $22.575 million in the comparable period. Chemistry, Manufacturing and controls costs were $4.814 million, while clinical operations accounted for $4.261 million. Personnel-related research and development expense was $8.989 million, including stock-based compensation, and other research and development expense was $2.026 million. For the nine months ended July 31, 2026, research and development expense was $64.540 million, compared with $62.758 million in the comparable period. General and administrative expense increased to $13.924 million from $7.372 million in the comparable period. Nine-month general and administrative expense was $32.627 million, compared with $20.926 million previously. Total operating expenses were $34.014 million for the quarter, compared with $29.947 million in the comparable period. Nine-month operating expenses were $97.167 million, compared with $83.684 million.

Equity And Share Count

Shareholders’ equity was $288.322 million as of July 31, 2026, compared with $221.468 million as of October 31, 2025. The company had 67,016,316 common shares outstanding as of September 2, 2026. The weighted-average share count used for the quarter’s basic and diluted per-share calculation was 69,734,610. The nine-month weighted-average count was 68,898,554.

Its primary uses of Capital are research and development, compensation and related costs, and general overhead.